Single Center Results following Proton Beam Therapy in Children with Atypical Teratoid Rhabdoid Tumors of the Central Nervous System
|
|
- Reginald Townsend
- 6 years ago
- Views:
Transcription
1 Single Center Results following Proton Beam Therapy in Children with Atypical Teratoid Rhabdoid Tumors of the Central Nervous System Christopher P. Haskins, BS; Babita Jyoti, MD; Matt Hines, RTT; Victor Simoneaux, RTT; and Jeffrey C. Buchsbaum, MD, PhD, AM Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract Submitted 12 Dec 2014 Accepted 04 Mar 2015 Published 20 Jul 2015 Corresponding author: Jeffrey C. Buchsbaum Department of Radiation Oncology Indiana University School of Medicine 535 Barnhill Dr, RT041 Indianapolis, IN 46202, USA Original Article DOI /IJPT * cc Copyright 2015 International Journal of Particle Therapy Distributed under Creative Commons CC-BY OPEN ACCESS Purpose: Atypical teratoid rhabdoid tumor is a rare, embryonal, central nervous system tumor seen predominantly in infancy and childhood. Outcomes are generally dismal, with median survival estimated at 6 months to a year. The purpose of this study was to evaluate proton beam therapy (PBT) outcomes in this population. Materials and Methods: Sixteen patients with a diagnosis of atypical teratoid rhabdoid tumor were treated from November 2007 to January 2013 at the Indiana University Health Proton Therapy Center. All patients were treated with PBT. Fraction sizes of 1.8 Gy/fraction were used to deliver 28 to 33 fractions. Seven patients received craniospinal PBT. There were 12 male and 4 female patients. The median age at diagnosis was 18.5 months (range, 5 months to 39 years). Eight had metastatic disease at diagnosis. Fourteen patients underwent surgery. Fifteen patients received chemotherapy. Results: Median survival follow-up time was 3.18 years (or 38.2 months). The mean overall survival was estimated at 5.6 years (or 67.2 months; 95% confidence interval, years). Patients of a median age of 18.5 months (range, months) received a median radiation dose to the tumor bed of 54 Gy (range, Gy). Eight patients also received craniospinal irradiation with a median dose of 36 Gy. Eleven patients showed no evidence of disease or stable disease, 3 patients were deceased, and 2 patients developed disease progression. Four patients suffered nausea and vomiting (common toxicity criteria [CTC] grade 2) as a result of treatment, and 4 patients also suffered moderate skin erythema (CTC grade 2). Two patients suffered from both weight loss and general fatigue during treatment. Conclusions: The PBT was well tolerated in this heavily treated population. In the background of poor survival, these early outcome data are promising. Additional followup is necessary. Keywords: atypical teratoid rhabdoid tumor; craniospinal irradiation; survival; proton therapy; pediatric radiation therapy Introduction Atypical teratoid/rhabdoid tumor (ATRT) is a rare, embryonic tumor of the central nervous system seen predominantly in infancy and childhood [1]. Its occurrence in adults is especially rare, and review of the literature reveals only a few case reports [2 4]. Recent How to cite this article Haskins CP, Jyoti B, Hines M, Simoneaux V, Buchsbaum JC. Single Center Results following Proton Beam Therapy in Children with Atypical Teratoid Rhabdoid Tumors of the Central Nervous System. Int J Particle Ther. 2015;2(1):1 10.
2 data suggest that much like medulloblastoma, multiple genetic subtypes are likely to exist within ATRT. Together, all the ATRT subtypes account for approximately 1% to 2% of pediatric brain tumors [5]. However, in patients under the age of 3 years, ATRT accounts for around 20% of malignant brain tumors [6]. Outcomes from this rare tumor are generally dismal, with median survival estimated at 6 months to a year [7, 8]. Prognostic factors include age at diagnosis and presence of germline mutations [9]. The tumor suppressor INI1 (hsnf5) found at 22q11.2 is frequently mutated in patients with ATRT, making it a risk factor and useful in diagnosis [6, 8]. Management is usually multimodal with surgical resection, chemotherapy, and radiation therapy. The use of radiation therapy in patients under the age of 3 years has been avoided in the past because of concerns about long-term neurocognitive damage. Outcomes appear to be better in older patients, where radiation therapy tends to be a more-significant part of the multimodal approach to treatment. In this single-center study of proton beam therapy (PBT) in patients with central nervous system ATRT, we report the outcomes of 16 patients treated during a period of 5 years at the Indiana University Health Proton Therapy Center (IUHPTC). Materials and Methods Sixteen patients with a diagnosis of ATRT were treated from November 2007 to January 2013 at IUHPTC. All 16 patients were included in the study. Institutional review board approval was obtained before patient records were reviewed. Patient names and medical charts were kept confidential. Fourteen of the 16 patients had surgery for maximal resection. Fifteen patients received chemotherapy. Six patients received chemotherapy according to Children s Oncology Group (COG) ACNS0333 protocol. This consists of 5 rounds of chemotherapy. Two induction cycles are administered, consisting of cisplatin, cyclophosphamide, etoposide, methotrexate, and vincristine. Peripheral-blood stem cells are harvested to provide support for the following 3 rounds of treatment. Proton therapy follows the 2 induction rounds, as specified. Following radiation, 3 consolidation cycles were administered consisting of carboplatin, thiotepa, and stem cell rescue. Patients who presented with metastatic disease at diagnosis received all 5 induction and consolidation rounds before radiation treatment. All patients were treated with image-guided 3D conformal proton therapy via uniform active scanning [10, 11]. Fraction sizes of 1.8 Gy/fraction were used to deliver between 28 and 33 fractions. Seven patients received craniospinal irradiation (CSI) to a dose between 23.4 to 36 Gy. A relatively uniform method for treatment simulation was employed for this patient population. In all cases, 1-mm slices were obtained during computed tomography simulation, which was performed in the treatment position with the patient immobilized on an alpha cradle with a facemask. The magnetic resonance imaging (MRI) was fused. The radiation oncologist defined target volumes using the Eclipse (version 11; Varian Medical Systems, Palo Alto, California) treatment planning system. The range compensators and spread-out Bragg peaks incorporated smearing to accommodate any setup uncertainties per routine as part of the treatment planning process. Custom-made, brass apertures and Lucite compensators were used for each field of radiation therapy. Two or more beams were used to treat the brain. The CSI was delivered using 2 posterior oblique beams to treat the brain and 2 posteroanterior spinal fields [12], and CSI treatments were feathered daily with 3 or 4 junctions. For all CSI treatments, 30-cm snout sizes were required for the spinal fields, and that was matched at the anterior spinal canal in all cases. Minimal dose at the junctions was 90% in all cases. Most patients were treated on the active COG protocol at the time. The patients that were not treated on protocol were treated with 5- to 10-mm clinical target volume margins and 2- to 3-mm planning target volume margins, plus smearing based on specific beam tissue pathways and immobilization methodologies per the judgment of the treating physician. For example, beams traversing sinus cavities were avoided, and those passing bone anatomy that could have variable depth based on small rotational variations were given larger degrees of smearing. The brainstem dose was kept to a point dose maximum of 59.4 Gy during any single course of therapy. The beams were allowed to stop in critical structures via the use of our in-house, published range-modulation technique [10]. Patient setup was verified on a field-by-field basis every fraction by a physician before the beam was delivered. Most of these patients had daily general anesthesia. We report the median radiographic follow-up time, which is the median time between radiation therapy (RT) completion and the last MRI on follow-up. The corresponding radiographic survival status is the disease progression based on the MRI (Tables 1 and 2). Progression-free survival (PFS) was used to evaluate these parameters (Figure 1). The PFS for patients 7 and 10 was measured as the interval time between treatments because reirradiation was initiated within 4 weeks of recurrence Haskins et al. (2015), Int J Particle Ther 2
3 Table 1. Treatment of patients with ATRT. Age beginning Patient, No. Sex RT at IUHPTC, y INI1 protein Metastases at diagnosis Tumor bed location Surgical resection Chemotherapy 1 Male 1.17 Left frontoparietal GTR Ara-C, Cis, Cyt, Dox, Mtx, VCR 2 Male 1 Right frontoparietal GTR Eto, Cis, Cy, VCR, Mesna, Metho 3 Male 0.83 Drop metastasis to C6 Posterior fossa STR 2 course agents not listed 4 Male 10 Left temporal GTR Cis, Cy, Dox, VCR 5 Female 0.42 þ Parietoccipital lobe GTR 2 cycles of carboplatin 6 Male 1.42 Posterior fossa STR 13 drugs but unknown which are of study Total tumor bed dose, cgy 5040 (XRTþprotons; 2520 proton boost) 4680 to cervical spine CSI dose, cgy Female 2.17 NT Posterior fossa STR Per protocol 5940, Male 2.5 Dorsal thoracic cord Third and left ventricles GTR Per protocol and cauda equine 9 Male 1.67 þ Posterior fossa GTR Cis, Cy, G-Csf, Mtx, VCR Male 1.92 Posterior fossa GTR Mtx, Leuco, Eto, Cy, Cis, Mesna, VCR , 5400* Female 0.67 ATRT on right side of bladder Pineal None Per protocol Male 1.67 þ Posterior fossa STR None Male 1.83 Posterior fossa GTR Per protocol Female 1.25 Drop metastasis to C7 Posterior fossa STR Per protocol 5400 and 4500 to cervical spin Male 1.08 NT Drop metastasis to cervical spine Right temporal, hypothalamic, Right cerebellar peduncle, Left temporal None Per protocol 4860 to brain and cervical spine 16 Male 39 RT temporal lobe STR BEP, VIP 5580 Abbreviations: ATRT, atypical teratoid rhabdoid tumor; IUHPTC, Indiana University Health Proton Therapy Center; CSI, craniospinal irradiation; GTR, gross total resection; STR, subtotal resection; Mtx, methotrexate; Dox, doxorubicin; Ara-C, cytarabine; VCR, vincristine; Cis, cisplatin; Cy, cytoxan; Eto, etoposide; Cy, cyclophosphamide; Carbo, carboplatin; G-Csf, granulocyte-colony stimulating factor; Lecuo, leucovorin; BEP, bleomycin, etoposide, cisplatin; VIP, vinblastine ifosfamide, cisplatin Notes: Per protocol: Children s Oncology Group ACNS0333: cisplatin, cyclophosphamide, etoposide, methotrexate, vincristine, carboplatin, thiotepa, stem cell rescue; distant disease, new metastasis shown on last magnetic resonance imaging; INI1 gene ( ), carries mutation a Patients 7 and 10 treated twice (Table 3). Each patient was censored at the time of his or her last radiographic scan on follow-up. Quartiles were computed for the 75% survival interval using SPSS Version 22 (IBM, Armonk, New York) for Macintosh (Apple, Cupertino, California). Actuarial PFS could not be calculated because of the small radiographic follow-up time. Median survival follow-up time is the median time between RT completion and a review of public health records to determine survival (Figure 2). Failure was defined as death from disease. The data were censored using the patient s last survival status based on review of public health records, the medical record, and direct communication by the families to our center. Families contacted the treating physician in all cases of death in this series. Haskins et al. (2015), Int J Particle Ther 3
4 Table 2. Outcomes of patients with ATRT. Patient, No. Sex Radiographic follow-up time, y Radiographic survival status Failure Secondary disease Survival follow-up, y Survival status 1 Male 1.33 NED 3.8 Alive 2 Male 0.34 NED 2.8 Alive 3 Male 2.15 Stable 4.78 Alive 4 Male 1.42 Stable AML 3.99 Alive 5 Female 2.49 NED 4.42 Alive 6 Male 4.16 NED 6.75 Alive 7 Female 2.41 DOD In field, left midbrain, base of skull 2.41 DOD 8 Male 0.42 DOD Yes 0.42 DOD 9 Male 2.2 Stable primary Medulla 3.72 Alive 10 Male 0.8 Stable Local and leptomeningeal spread (before retreatment) 2.44 Alive 11 Female 2.59 Stable Thecal nerve root, 8 mo; now stable 3.57 Alive 12 Male 0 NED 2.19 Alive 13 Male 0.36 NED 2.11 Alive 14 Female 0 Stable 2.11 Alive 15 Male 0.04 DOD Lung during treatment 0.04 DOD 16 Male 2.34 Stable 4.82 Alive Abbreviations: DOD, dead of disease; NED, no evidence of disease; AML, acute myeloid lymphoma. The median survival follow-up was also used to compare the survival of patients presenting with metastatic disease to those without it. The factors were compared using SPSS software, significance was calculated using Log rank with data pooled over strata, and a third Kaplan-Meier curve was generated (Figure 3). Mean survival time for both groups is reported because the median overall survival (OS) between factors could not be calculated. The IUHPTC was a quaternary referral center that received patients mainly from across the Midwest. Radiographic followup was setup outside of our department. Because of the center s recent closure, we could not extend the follow-up time to generate a median OS or actuarial PFS. The median survival follow-up time allowed extension of the follow-up for survival status only. Results Sixteen patients with a diagnosis of ATRT were treated with proton therapy at the IUHPTC between November 2007 and January There were 12 male and 4 female patients. The median age at the beginning of RT was 18.5 months (or 1.54 years), with a range of 5 months to 39 years. Five (31.5%) of these patients had metastatic disease at diagnosis. Of the 14 patients whose Figure 1. Each failure is marked by disease progression either locally or distant, as measured on radiographic follow-up, or by death from disease. The patients were censored if radiographic follow-up showed no disease progression. At 1.42 years, 75% of patients maintained progression-free survival (PFS). Haskins et al. (2015), Int J Particle Ther 4
5 Table 3. Patients with reirradiation. Patient, No. First treatment dose to tumor bed, Gy Pattern of failure Interval time between treatments, y Second treatment dose to tumor bed, Gy Sum dose, Gy Radiographic survival status Localþ midbrain DOD Local þ leptomeningeal Spread Stable pathology was tested for INI-1 protein, 11 had the INI-1 mutation. Three had uncertain histologies, where the diagnosis remained ATRT and scant tissue. Two patients were not tested for the INI-1 mutation and the date of diagnosis may have made testing less certain for older cases [13]. Testing was performed at the referring institutions if from out of state. Some patients from out of the country had central review in their country s preeminent center. Patients in our center had review either at Cincinnati Children s Hospital or at Johns Hopkins Hospital, if we were in doubt of the diagnosis and had access to the tissue. Fourteen patients underwent surgery, 6 (35%) had subtotal resection and 8 (47%) had gross-total resections. Two patients (11%), both with metastatic disease at diagnosis, did not undergo surgery. One of these patients received a cranial dose of 54 Gy. The second patient received a palliative dose (30.6 Gy) to the brain and a boost of 18 Gy to the spine. All patients started radiation within 8 weeks of tissue diagnosis. Staging and treatment were per initial staging, and no progression was noted from diagnosis to simulation in our cohort. Fifteen patients received chemotherapy. Six of those patients were treated according to the COG protocol, and the rest received the chemotherapy regimens as shown in Tables 1 and 2. One patient received chemotherapy concomitantly with radiation (patient 4 received vincristine during RT). The median radiation dose to the tumor bed for all patients was 54 Gy. In addition, 8 patients received CSI irradiation with a median dose of 36 Gy. Of these, 4 were patients with metastatic disease. Patient 3 received both XRT and proton therapy for a combined dose of 50.4 Gy to the tumor bed (25.2 Gy from protons), and 46.8 Gy to a cervical spine metastasis. Patients 3, 14, and 15 also received a boost to spinal metastases to a dose of 46.8, 45, and 46.8 Gy, respectively. Patients 7 and 10 were treated twice. For the retreated patients, Table 3 shows the doses for treatments 1 and 2 and the interval time between treatments. Patient 7 received 59.4 Gy to the posterior fossa 18.4 months before primary recurrence and reirradition. Patient 10 received 50.4 Gy to the posterior fossa 8 months before reirradition for local recurrence and leptomeningeal spread. Outcomes The median follow-up time after completion of radiation was 3.18 years (or 38.2 months), at which point 13 of 16 patients (81%) were alive (Figure 1). Estimated from the curve, the mean OS was 5.6 years (or 67.2 months; 95% confidence interval [CI], Figure 2. The 3 failures mark the 3 patients who died of disease. The patients were censored at the last survival follow-up. Currently, 81% of patients are living at a median survival follow-up of 3.18 years (or 38.2 months) and a mean overall survival (OS) of 5.6 years (or 67.2 months; 95% confidence interval [CI], years). Haskins et al. (2015), Int J Particle Ther 5
6 Figure 3. The green represents the 5 patients who presented with metastatic disease, and the blue shows the 11 patients that did not. The failures represent death from disease. Each patient was censored at the last survival follow-up time. The factors were compared (P ¼ 0.098). The mean overall survival (OS) for the group with metastatic disease at diagnosis was estimated at 2.96 years (95% confidence interval [CI], years) and for the group without metastasis at 6.27 years (95% CI, years) years). The median radiographic follow-up time was 1.38 years (or 16.6 months; range, years); at which point, 11 patients had no evidence of disease or stable disease, 1 patient was suffering from distant relapse, 3 patients were dead from disease, and 1 patient developed a secondary acute myeloid leukemia (AML). The crude PFS of 75% was at a follow-up time of 1.42 years (Figure 2), just exceeding the median radiographic follow-up. There were 6 ATRT failures. Two failures were marginal, and the patients were retreated (patients 7 and 10). Patient 7 had a subtotal resection, chemotherapy, and received 54 Gy with a boost to 59.4 Gy at 1.8 Gy per fraction. The patient developed recurrent disease 1.6 years later and was retreated with 36 Gy CSI with a boost to 59.4 Gy to the tumor bed. Patient 7 suffered tumor growth in the frontal lobe and base of the skull and died in hospice 8 months after retreatment from disease. Her plans are shown in Figure 3. Patient 10 was stable 9.6 months after retreatment and had similar dosing to patient 7, including salvage via craniospinal radiation to 36 Gy. Four ATRT failures were widespread, one of which developed lung metastases and caused early withdrawal of treatment (patient 15). Patient 15 did not undergo surgery, but did receive chemotherapy and a palliative proton radiation dose of 30.6 Gy to the tumor bed, 48.6 Gy to the cervical spine, and 30.6 Gy CSI. Three patients developed distant relapse following RT. Patient 8 had a gross total resection, chemotherapy, and 50.4 Gy to the tumor bed with 36 Gy CSI. The patient developed metastasis and died of disease 5 months after RT, although the location of metastasis was not available to us. Patient 9 developed metastasis to the medulla 2.2 years following multimodal treatment and is currently undergoing further chemotherapy. Patient 11 was metastatic at diagnosis and developed secondary thecal nerve-root metastases following multimodal treatment but became stable following an additional 8 rounds of chemotherapy. The patient s MRI showed stable disease on the most recent follow-up. Of the 6 ATRT failures, 3 died of disease, 2 were stable on last follow-up, and 1 patient was still suffering from distant relapse. Patient 4 developed secondary AML 19 months after treatment with 54 Gy to brain and 23.4 Gy CSI. Toxicity The most common radiation-associated toxicities were nausea, vomiting, and skin erythema. Four patients suffered nausea and vomiting (CTC grade 2) as a result of treatment, and 4 patients suffered moderate skin erythema (CTC grade 2). Two patients suffered from both weight loss and general fatigue during treatment. Patient 4 had significant hearing difficulty in the left ear because of cochlear damage that was unavoidable because of tumor involvement adjacent to the cochlea. Hematologic toxicity was managed either by the referring teams or our medical oncology team. In no case, did hematologic toxicity cause treatment delay, bleeding, or febrile neutropenia. We do not have complete access to those data because we were a quaternary referral center. No radiation necrosis was seen in our patient population, but radiation-associated change was seen in some cases prompting a short course (, 4 weeks) of steroid treatment. Haskins et al. (2015), Int J Particle Ther 6
7 Figure 4. (A) The left hand 3 images show the retreatment plan with careful effort used to spare the chiasm because of some dose to the chiasm (shown in orange-yellow) being delivered in the penumbra of the first plan, shown on the right 3 images. The dose-volume histogram shows the optic chiasm region for both plans. The targets are shown in red (gross tumor volumes) for each plan, respectively. The relapse was felt to be multifocal and not a simple marginal miss, so craniospinal irradiation (CSI) was employed. The patient has a laryngeal mask airway in place. (B) Orange and red reflect areas. 100 Gy. One of 2 patients treated with doses. 100 Gy is doing well several years from having leptomeningeal disease. In our series (data presented at PROS 2013) looking at retreatment at a cohort of patients with glioma and significant chemotherapy exposure, we saw 10% radiation necrosis for this range of dose in our center Discussion Although ATRT remains a dismal diagnosis, increasing evidence demonstrates promising outcomes for patients with ATRT treated with proton therapy. Our results are comparable to survival outcomes reported in the literature by groups treating with both proton and photon irradiation. There are 3 other studies to our knowledge that look at ATRT treatment using proton therapy. Bernstein et al [14] reported 9 patients (median age, 2.3 years) without evidence of primary disease at a median follow-up time of 27.3 months. Only 2 of their patients suffered distant relapse, and only 1 died of disease. Weber et al [15] reported on 15 children (median age, years) at a median follow-up of 33.4 months. Local failure was seen in 20% of patients. Distant failure was divided up into distant brain failure at 27% and distant spine failure at 13%. Median OS was 64.6% in their series. Six patients died from tumor progression in their series, and they did not find an association between young age and outcome. McGovern et al [16] reported 31 patients (median age, 2 years) with a median follow-up time of 24 months. Radiation (planned course) completion was seen in 87% of their cohort. Progression was seen in 16% of their patients. Thirteen (42%) were known to have died. The PFS2 after radiation therapy was 45.9%, and the OS2 from the end of radiation was 53%. Similarly, at a median follow-up of 3.18 years (or 38.2 months), 81% of our patients were alive. All but one (94%) of our patients completed their course, and 2 completed full retreatment courses of at least 54 Gy. Our survival rates are in line with survival rates predicted by Chi et al [17], who described an estimated future OS2 rate of 70% 6 10%. Haskins et al. (2015), Int J Particle Ther 7
8 Although radiation therapy to young children is still debated, the literature reports increased OS rates in the treatment of ATRT, evidence that the benefits may far outweigh the risks. Buscariollo et al [6] looked at 144 patients in Surveillance, Epidemiology, and End Results (SEER) program, National Cancer Institute, Bethesda, Maryland) with ATRT from 1973 to Patients that did not receive RT had a median OS of 6 months compared with a median OS that was not yet reached at 34 months for those who received RT. This was shown to be a significant predictor of survival in a multivariate analysis (hazard ratio ¼ 0.10; 95% CI, ; P ¼ 0.02). These data suggest RT has an important role in the multimodal approach to treatment to drastically increase survival times. There is some evidence that survival rates are affected by the age of the patient receiving RT. A study by Bishop et al [18] reported on the SEER database with submissions of primary brain tumors in infants (, 12 months old) from 1973 to Infants (, 12 months) with ATRT had the lowest survival rate. Those infants treated with surgery alone had a 12-month survival of 24.4% [18]. However, the 12-month survival increased to 100% with immediate adjuvant radiation therapy. We report a similar rate in this age group. Although only 4 of our patients were, 12-months old, all 4 patients treated with proton radiation show no evidence of disease or stable disease with a radiographic median follow-up time of 2.35 years (or 28.2 months), and a median survival follow-up of 3.89 years (or 46.7 months). Indeed, our data suggest that the youngest of the patients with ATRT may gain the most from early, adjuvant radiation therapy. Some data suggests early metastatic disease may be the strongest predictor of failure. Buscariollo et al [6] reported a significant difference in median OS between patients who presented with metastatic disease at diagnosis (13% of the cohort; median OS, 3 months) and those who had focal disease (median OS, 6 months). Multivariate analysis showed metastatic disease present at diagnosis to be another independent factor of survival status (hazard ratio 2.83; 95% CI, ; P ¼ 0.001). These findings are consistent with other studies in the literature that show metastatic progression at presentation to be an independent risk factor [19, 20]. Metastatic disease at presentation in patient cohorts with ATRT is typically 13% to 33% [6, 8, 17, 21, 22]. At 31.5%, our patients were on the high end of that range. Of the 5 patients with metastasis in our cohort, 2 are dead of disease, 1 developed distant metastasis and treatment is unknown at the time of writing, and 2 have stable scans. The median survival follow-up times were compared between groups (Figure 3; P ¼ 0.098). The median OS rate could not be calculated; however, the current median survival follow-up time of the 5 patients alone is 2.11 years (or 25.3 months), which exceeds some of the previous averages of ATRT survival. In addition, the mean OS for the group with metastases at diagnosis was estimated at 2.96 years (95% CI, years), and the mean OS for the nonmetastatic group was estimated at 6.27 years (95% CI, years). We have one unusual case of an older individual with confirmed histology having long survival for metastatic disease without CSI. It is unclear whether adults have unusual survival in this disease or if they respond differently to systemic therapy. Our series used uniform active scanning techniques in all cases and our in-house method of modulating the end of the beam s increased biologic dose [10]. No patients in our cohort needed either hyperbaric oxygen or bevacizumab for radiation necrosis, even in the case of retreatment. The major limitations in this study are the short follow-up time and the size of the patient population studied. Because of the impending closure of IUHPTC, we could not extend the follow-up time. As it was, sufficient patients had not passed away to calculate more-optimal statistics. Hopefully, the current COG study will yield new insights because of the larger sample size. Lastly, because IUHPTC is a quaternary referral center, our study may have referral bias. More-palliative cases of ATRT in the referral region may have stayed at their home institution. We present promising results as the fourth study looking at proton irradiation in ATRT. It will be interesting to see whether proton beam therapy can be evaluated on the COG study or within the pediatric proton consortium registry [10] as late effect and further genetic data evolve. These data suggest that PBT may be a good option for young children with ATRT. ADDITIONAL INFORMATION AND DECLARATIONS Conflicts of interest: The authors have no conflicts to disclose. Acknowledgments: We wish to thank Stephanie Dickenson at the Indiana Statistical Counseling Center (Bloomington). References 1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215 25; discussion Haskins et al. (2015), Int J Particle Ther 8
9 2. Pimentel J, Silva R, Pimentel T. Primary malignant rhabdoid tumors of the central nervous system: considerations about two cases of adulthood presentation. J Neurooncol. 2003;61: Lutterbach J, Liegibel J, Koch D, Madlinger A, Frommhold H, Pagenstecher A. Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature. J Neurooncol. 2001;52: Arrazola J, Pedrosa I, Mendez R, Saldana C, Scheithauer BW, Martinez A. Primary malignant rhabdoid tumour of the brain in an adult. Neuroradiology. 2000;42: Lafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer S, Wilson B, Jabado N, Scheinemann K, Eisenstat D, Fryer C, Fleming A, Mpofu C, Larouche V, Strother D, Bouffet E, Huang A. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer. 2012;48: Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer. 2012;118: Athale UH, Duckworth J, Odame I, Barr R. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol. 2009;31: Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithauer BW, Walter AW, Rorke LB, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22: Kordes U, Gesk S, Fruhwald MC, Graf N, Leuschner I, Hasselblatt M, Jeibmann A, Oyen F, Peters O, Pietsch T, Siebert R, Schneppenheim R. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer. 2010;49: Kasper HB, Raeke L, Indelicato DJ, Symecko H, Hartsell W, Mahajan A, Hill-Kayser C, Perkins SM, Chang AL, Childs S, Buchsbaum JC, Laurie F, Khan AJ, Giraud C, Yeap BY, Yock TI. The Pediatric Proton Consortium Registry: a multiinstitutional collaboration in U.S. proton centers. Int J Particle Therapy. 2014;1: Farr JB, Mascia AE, Hsi WC, Allgower CE, Jesseph F, Schreuder AN, Wolanski M, Nichiporov DF, Anferov V. Clinical characterization of a proton beam continuous uniform scanning system with dose layer stacking. Med Phys. 2008;35: Buchsbaum JC, Besemer A, Simmons J, Hoene T, Simoneaux V, Sandefur A, Wolanski M, Li Z, Cheng CW. Supine proton beam craniospinal radiotherapy using a novel tabletop adapter. Med Dosim. 2013;38: Hasselblatt M, Kordes U, Wolff J, Jeibmann A, Fruhwald MC, Paulus W. Pitfalls in the diagnosis of atypical teratoid/ rhabdoid tumors (AT/RT): experiences from the European Rhabdoid Tumor Registry (EURHAB) and the International Choroid Plexus Tumor Registry (CPT-SIOP). Neuro Oncology. 2012;14: De Amorim Bernstein K, Sethi R, Trofimov A, Zeng C, Fullerton B, Yeap BY, Ebb D, Tarbell NJ, Yock TI, MacDonald SM. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys. 2013;86: Weber DC, Ares C, Malyapa R, Albertini F, Calaminus G, Kliebsch U, Mikroutsikos L, Morach P, Bolsi A, Lomax T, Schneider R. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy. J Neurooncol. 2015;121: McGovern SL, Okcu MF, Munsell MF, Kumbalasseriyil N, Grosshans DR, McAleer MF, Chintagumpala M, Khatua S, Mahajan A. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014;90: Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27: Bishop AJ, McDonald MW, Chang AL, Esiashvili N. Infant brain tumors: incidence, survival, and the role of radiation based on Surveillance, Epidemiology, and End Results (SEER) Data. Int J Radiat Oncol Biol Phys. 2012;82: von Hoff K, Hinkes B, Dannenmann-Stern E, von Bueren AO, Warmuth-Metz M, Soerensen N, Emser A, Zwiener I, Schlegel PG, Kuehl J, Fruhwald MC, Kortmann RD, Pietsch T, Rutkowski S. Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer. 2011;57: Haskins et al. (2015), Int J Particle Ther 9
10 20. Pai Panandiker AS, Merchant TE, Beltran C, Wu S, Sharma S, Boop FA, Jenkins JJ, Helton KJ, Wright KD, Broniscer A, Kun LE, Gajjar A. Sequencing of local therapy affects the pattern of treatment failure and survival in children with atypical teratoid rhabdoid tumors of the central nervous system. Int J Radiat Oncol Biol Phys. 2012;82: Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85: Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH. Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys. 2006;64: Haskins et al. (2015), Int J Particle Ther 10
Case Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child
Case Reports in Oncological Medicine Volume 2013, Article ID 815923, 4 pages http://dx.doi.org/10.1155/2013/815923 Case Report Atypical Presentation of Atypical Teratoid Rhabdoid Tumor in a Child Y. T.
More informationRole of adaptive radiation therapy for pediatric patients with diffuse pontine glioma
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 12, NUMBER 2, spring 2011 Role of adaptive radiation therapy for pediatric patients with diffuse pontine glioma Chris Beltran, a Saumya Sharma, and Thomas
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM EPENDYMOMA Last Revision Date July 2015 1 CNS Site Group Ependymoma Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2.
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationEpendymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients
ORIGINAL ARTICLE Brain Tumor Res Treat 2017;5(2):70-76 / pissn 2288-2405 / eissn 2288-2413 https://doi.org/10.14791/btrt.2017.5.2.70 Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective
More informationIntracranial AT RT / radiotherapy. Therapeutic dilemma / radiotherapy
Therapeutic dilemma / radiotherapy Agressive tumour, poor outcome Past treatments based on MB concepts (RT CSA) MB Overall survival Mean age : 6.52 years n=36, 5 year 75% 1. Tumour occurs in the very young
More informationLeptomeningeal Carcinomatosis: Risks, Detection, and Treatment. Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania May 13, 2016 Disclosures None to declare 2 Outline Epidemiology
More informationProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors (SIOPCNSGCTII)
1 von 9 10.12.2013 09:03 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: UKM08_0057 Previous Study Return to List Next Study Prospective Trial for the Diagnosis and Treatment
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More information1 Department of Pediatric Hematology and Oncology, University. 3 Department of Pediatrics, University of Erlangen, Erlangen,
Pediatr Blood Cancer 2011;57:978 985 Frequency, Risk-Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German
More informationHematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: Original Effective Date: MM.07.013 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 02/24/2012
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM GERM CELL TUMOURS CNS Site Group Germ Cell Tumours Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationReducing excess radiation from portal imaging of pediatric brain tumors
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 14, NUMBER 5, 2013 Reducing excess radiation from portal imaging of pediatric brain tumors Moses Tam, 1 Maya Mathew, 1 Christine J. Hitchen, 1 Ashwatha
More informationCase Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
Oncology Volume 2009, Article ID 247873, 4 pages doi:10.1155/2009/247873 Case Report Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
More informationRadiation therapy is the most effective adjuvant therapy in children
CLINICAL REPORT PEDIATRICS Imaging Changes in Very Young Children with Brain Tumors Treated with Proton Therapy and Chemotherapy N.D. Sabin, T.E. Merchant, J.H. Harreld, Z. Patay, P. Klimo, Jr, I. Qaddoumi,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MEDULLOBLASTOMA AND PNET CNS Site Group Medulloblastoma and PNET Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationORIGINAL ARTICLE. Children s Hospital Augsburg, Augsburg, Germany; Germany;
Bone Marrow Transplantation (2014) 49, 370 375 & 2014 Macmillan Publishers Limited All rights reserved 0268-3369/14 www.nature.com/bmt ORIGINAL ARTICLE High-dose chemotherapy (HDCT) with auto-sct in children
More informationIntensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain
1 Carol Boyd March Case Study March 11, 2013 Intensity modulated radiotherapy (IMRT) for treatment of post-operative high grade glioma in the right parietal region of brain History of Present Illness:
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationBrain Tumors in Children
Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma
More informationCase Report Tackling a Recurrent Pinealoblastoma
Case Reports in Oncological Medicine, Article ID 135435, 4 pages http://dx.doi.org/10.1155/2014/135435 Case Report Tackling a Recurrent Pinealoblastoma Siddanna Palled, 1 Sruthi Kalavagunta, 1 Jaipal Beerappa
More informationAtypical Teratoid / Rhabdoid tumours. Information for parents and carers
Atypical Teratoid / Rhabdoid tumours Information for parents and carers Grace Kelly Ladybird Trust Atypical Teratoid / Rhabdoid tumours This publication is intended to supplement the advice given by your
More informationChildhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ )
1 di 10 27/06/2016 08.16 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute
More informationSelecting the Optimal Treatment for Brain Metastases
Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,
More informationImaging Findings of CNS Atypical Teratoid/Rhabdoid Tumors
AJNR Am J Neuroradiol 25:476 480, March 2004 Case Report Imaging Findings of CNS Atypical Teratoid/Rhabdoid Tumors Atilla Arslanoglu, Nafi Aygun, Deapak Tekhtani, Leslie Aronson, Ken Cohen, Peter C. Burger,
More informationRadiation therapy is the most effective adjuvant therapy in
Published July 19, 2012 as 10.3174/ajnr.A3219 CLINICAL REPORT N.D. Sabin T.E. Merchant J.H. Harreld Z. Patay P. Klimo, Jr I. Qaddoumi G.T. Armstrong K. Wright J. Gray D.J. Indelicato A. Gajjar Imaging
More informationThe technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationSCIENTIFIC PROGRAMME SNOLA THE STATE OF THE ART ON NEURO-ONCOLOGY th March
SCIENTIFIC PROGRAMME SNOLA THE STATE OF THE ART ON NEURO-ONCOLOGY 2018 15th March 13h 13h45 ROOM 1 ROOM 2 ROOM 3 Imaging and pathology case discussion Lymphomas case discussion- Meningeomas Moderator:
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationReirradiation of Recurrent Pediatric Brain Tumors after Initial Proton Therapy
Reirradiation of Recurrent Pediatric Brain Tumors after Initial Proton Therapy Benjamin Farnia, MD 1,2 ; Nancy Philip, MD 2 ; Rola H. Georges, CMD 2 ; Mary Frances McAleer, MD, PhD 2 ; Matthew Palmer,
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationEvaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation
Min et al. Radiation Oncology 2014, 9:220 RESEARCH Open Access Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation Chul Hee Min 1,2, Harald Paganetti 1,
More informationWilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations
Wilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations Background: The Duval County Medical Society (DCMS) is proud to provide its members with free continuing medical
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationA Dosimetric Comparison of Whole-Lung Treatment Techniques. in the Pediatric Population
A Dosimetric Comparison of Whole-Lung Treatment Techniques in the Pediatric Population Corresponding Author: Christina L. Bosarge, B.S., R.T. (R) (T) Indiana University School of Medicine Department of
More informationTo Reduce Hot Dose Spots in Craniospinal Irradiation: An IMRT Approach with Matching Beam Divergence
SCIENCE & TECHNOLOGY To Reduce Hot Dose Spots in Craniospinal Irradiation: An IMRT Approach with Matching Beam Divergence Alburuj R. Rahman*, Jian Z. Wang, Dr. Z. Huang, Dr. J. Montebello Department of
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationPathologic Characteristics and Treatment Outcome of Patients with Malignant Brain Tumors: A Single Institutional Experience from Iran
Middle East Special Report Middle East Journal of Cancer; April 2014; 5(2): 91-96 Pathologic Characteristics and Treatment Outcome of Patients with Malignant Brain Tumors: A Single Institutional Experience
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationOutcome and Prognostic Features in Pediatric Gliomas
Outcome and Prognostic Features in Pediatric Gliomas A Review of 6212 Cases From the Surveillance, Epidemiology, and End Results Database Ibrahim Qaddoumi, MD, MS 1 ; Iyad Sultan, MD 2 ; and Amar Gajjar,
More information8/3/2016. Clinical Significance of RBE Variations in Proton Therapy. Why RBE (relative biological effectiveness)?
8//06 Clinical Significance of Variations in Proton Therapy H. Paganetti PhD Professor, Harvard Medical School Director of Physics Research, Massachusetts General Hospital, Radiation Oncology Introduction
More informationStandard care plan for Prophylactic Cranial Irradiation for Limited Stage (stage I-III) Small Cell Lung Cancer (25Gy in 10 fractions) References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Prophylactic Cranial Irradiation for Limited-stage Small Cell Lung Cancer (20Gy in 5 fractions) Clinical Guideline Standard Care
More informationHigh grade glioma + brainstem glioma
+ brainstem glioma Highly agressive tumours Median survival ca 9-12 months Curative or palliative treatments? Intensity of treatment Side effects Quality of life issues + brainstem glioma Aims of radiotherapy
More informationChika Nwachukwu, Ph.D. MS IV Radiation Oncology Rotation
Chika Nwachukwu, Ph.D. MS IV Radiation Oncology Rotation Background Histology/Tumor Characteristics Presenting Symptoms/diagnosis Treatment/outcome Patient cohort Research on HRQOL Slow growing indolent
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Role of post-operative radiation therapy in single brain metastasis from clear cell sarcoma in children: a case report with systemic review Fadoua Rais, Naoual Benhmidou,
More information7/1/2015. Radiotherapy in Infant Brain Tumors. Goals and Objectives. Primary Brain and CNS Tumors (0-14 years) Brain Tumors (1 to 4 years)
Radiotherapy in Infant Brain Tumors ARNOLD C. PAULINO, M.D. PROFESSOR OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER AND TEXAS CHILDREN S HOSPITAL Radiotherapy in Infant Brain Tumors 1. Try to Avoid Irradiation
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationFirst, how does radiation work?
Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationA Case Study: Proton Therapy for Male Breast Cancer with Previous Irradiation
A Case Study: Proton Therapy for Male Breast Cancer with Previous Irradiation Bosco Q. Giap, BA 1 ; Fantine Giap, BA 2 ; John P. Einck, MD 3 ; Richard LePage, PhD 4 ; Dana M. Blasongame, CMD 4 ; Angela
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationMedulloblastoma is the most common malignant brain
CLINICAL AND LABORATORY OBSERVATIONS Chronic Residual Lesions in Metastatic Medulloblastoma Patients Iris Fried, MD,*w Annie Huang, MD, PhD,* Ute Bartels, MD,* Uri Tabori, MD,* Normand Laperriere, MD,z
More informationHematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: 8.01.28 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationEvaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas
1 Carol Boyd Comprehensive Case Study July 11, 2013 Evaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas Abstract: Introduction:
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationGuidelines for management of Atypical Teratoid Rhabdoid Tumours. CCLG Neuro-oncology Special Interest Group. Version 2.2, May 2011.
Guidelines for management of Atypical Teratoid Rhabdoid Tumours CCLG Neuro-oncology Special Interest Group Version 2.2, May 2011 Review date Contributors: Dr Stephen Lowis Dr Gary Nicolin Dr Barry Pizer
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationKey Words. Infants Brain tumors Chemotherapy Radiation therapy
The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Pediatric Oncology Current
More informationRadiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN
Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationSacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor
More informationCharged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions
Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Policy Number: 8.01.10 Last Review: 11/2017 Origination: 11/2006 Next Review: 11/2018 Policy Blue Cross and Blue Shield of
More information-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
More informationStereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas
Stereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas Treatment Results on the Basis of a 22-Year Experience Bruce E. Pollock, MD 1,2 ; Scott L. Stafford, MD
More informationMedulloblastoma / high risk. Radiotherapy in high risk medulloblastoma
Radiotherapy in high risk medulloblastoma PROS Meeting London 4.-6. October 2012 Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, 04107 Leipzig/Germany
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationAdult-Onset Sellar and Suprasellar Atypical Teratoid Rhabdoid Tumor Treated with a Multimodal Approach: A Case Report
CASE REPORT Brain Tumor Res Treat 2014;2(2):108-113 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2014.2.2.108 Adult-Onset Sellar and Suprasellar Atypical Teratoid Rhabdoid Tumor
More informationDisclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
More informationIntensity Modulated Radiotherapy (IMRT) for Central Nervous System (CNS) Tumors and Vertebral Tumors
Medical Policy Manual Medicine, Policy No. 147 Intensity Modulated Radiotherapy (IMRT) for Central Nervous System (CNS) Tumors and Vertebral Tumors Next Review: August 2018 Last Review: November 2017 Effective:
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More informationTreatment of Recurrent. Central Nervous System. Primitive Neuroectodermal Tumours (PNETs) in Children and Young People. Version 1.
Treatment of Recurrent Central Nervous System Primitive Neuroectodermal Tumours (PNETs) in Children and Young People Version 1.0 September 2011 Barry Pizer on behalf of the CCLG CNS Interest Group Guidance
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationAMERICAN BRAIN TUMOR ASSOCIATION. Proton Therapy
AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationIntrafractional Junction Shifts Utilizing Multileaf Collimation: A Novel CSI Planning Technique. Rodney Hood RT(R)(T)CMD
Intrafractional Junction Shifts Utilizing Multileaf Collimation: A Novel CSI Planning Technique Rodney Hood RT(R)(T)CMD Happy Father s Day! Quiet Room Beam me up Scotty! What is CSI? CSI-DURHAM! CSI Craniospinal
More informationDescription. Section: Therapy Effective Date: July 15, 2015 Subsection: Original Policy Date: September 13, 2012 Subject: Page: 1 of 10
Last Review Status/Date: June 2015 Page: 1 of 10 Description Radiotherapy (RT) is an integral component in the treatment of many brain tumors, both benign and malignant. Intensity-modulated radiation therapy
More informationHematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma
Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma Policy Number: Original Effective Date: MM.07.013 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/22/2016
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationExploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future
Exploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future Daniel Gasic Disclosure Nothing to disclose Introduction Background
More informationInstitute of Oncology & Radiobiology. Havana, Cuba. INOR
Institute of Oncology & Radiobiology. Havana, Cuba. INOR 1 Transition from 2-D 2 D to 3-D 3 D conformal radiotherapy in high grade gliomas: : our experience in Cuba Chon. I, MD - Chi. D, MD - Alert.J,
More informationRadiation necrosis is a well-described toxicity that has been
ORIGINAL RESEARCH PEDIATRICS Radiation Necrosis in Pediatric Patients with Brain Tumors Treated with Proton Radiotherapy X S.F. Kralik, C.Y. Ho, W. Finke, J.C. Buchsbaum, C.P. Haskins, and C.-S. Shih ABSTRACT
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationA simple technique for craniospinal radiotherapy in the supine position
Radiotherapy and Oncology 78 (2006) 217 222 www.thegreenjournal.com Craniospinal radiotherapy A simple technique for craniospinal radiotherapy in the supine position William A. Parker a, *, Carolyn R.
More informationProtocol. Intensity-Modulated Radiation Therapy (IMRT): Central Nervous System Tumors
Intensity-Modulated Radiation Therapy (IMRT): Central Nervous (80159) Medical Benefit Effective Date: 03/01/14 Next Review Date: 03/15 Preauthorization No Review Dates: 07/12, 07/13, 03/14 The following
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 7 MARCH 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS
More informationTheodore S. Johnson, MD, PhD
Front-line Therapy of DIPG Using IDO Pathway Inhibitor Indoximod in Combination with Radiation and Chemotherapy American Association of Cancer Research (AACR) 2018 Theodore S. Johnson, MD, PhD Georgia
More informationIntensity Modulated Radiation Therapy (IMRT): Central Nervous System Tumors. Original Policy Date
MP 8.01.36 Intensity Modulated Radiation Therapy (IMRT): Central Nervous System Tumors Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Created with literature
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More information